Compartmentation of cAMP in cardiomyocytes

Grégoire Vandecasteele, Rodolphe Fischmeister

► To cite this version:

Grégoire Vandecasteele, Rodolphe Fischmeister. Compartmentation of cAMP in cardiomyocytes. Handbook of Cell Signaling - 2nd ed., Oxford Academic Press., pp. 1581-1588., 2009, 10.1016/B978-0-12-374145-5.00195-9 . hal-02940490

HAL Id: hal-02940490

<https://hal.science/hal-02940490>

Submitted on 16 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

cAMP specificity in the heart

Compartmentation of cAMP in cardiomyocytes

Grégoire Vandecasteele & Rodolphe Fischmeister

¹INSERM UMR-S 769, F-92296, Châtenay-Malabry, France

²Univ. Paris-Sud 11, IFR141, F-92296, Châtenay-Malabry, France

Correspondence to:

Dr. Rodolphe FISCHMEISTER
INSERM U-769
Université Paris-Sud 11
Faculté de Pharmacie
5, Rue J.-B. Clément
F-92296 Châtenay-Malabry Cedex
France

Tel. 33-1-46 83 57 71
Fax 33-1-46 83 54 75
E-mail: rodolphe.fischmeister@inserm.fr

Summary

The second messenger cAMP is responsible for β -adrenergic receptor (β -AR) stimulation of cardiac function by catecholamines, but is also elevated in response to several other receptors which exert distinct functional effects on the heart. Evidences that spatial segregation of cAMP signalling may explain these observations are reviewed in this chapter. In particular, the role of cell architecture and the molecular mechanisms that restrict cAMP signals will be detailed.

Key words: hormone-heart-cAMP-compartmentation-phosphodiesterase

Introduction

The concept of compartmentalized signaling stems from studies of the cAMP pathway in the heart (reviewed in Steinberg & Brunton, 2001 [1]). In cardiac myocytes, intracellular cAMP levels can be augmented by catecholamine as well as by a large number of hormones and circulating factors. These different “first messengers” act through specific heptahelical receptors coupled to heterotrimeric G_s proteins, which activate cAMP synthesis by adenylyl cyclases (AC). In some cases, such as catecholamine or isoprenaline (ISO) binding to β_1 -adrenergic receptors (β_1 -AR), cAMP elevation causes a dramatic increase in cardiac beating frequency (positive chronotropy), in cardiac force of contraction (positive inotropy) and in cardiac relaxation speed (positive lusitropy). These effects are mainly due to the concerted phosphorylation of key proteins of the excitation-contraction coupling (ECC) by cAMP-dependent protein kinase (PKA): L-type Ca^{2+} channels (LTCC), phospholamban (PLB), ryanodine receptors (RyR) and troponin I (TnI) (Figure 1) [2]. However, in other cases, such as prostaglandin E1 (PGE_1) binding to prostanoid receptors (EP-R), a comparable elevation of cAMP does not lead to phosphorylation of ECC proteins and does not produce the robust functional response that characterizes β_1 -AR stimulation. A first clue to this paradoxical observation was the identification of two PKA isozymes (PKAI and PKAII) in myocardium, differing by the nature of their regulatory subunits (called RI and RII) and by their distribution: whereas PKAI was mostly soluble, PKAII was associated to the particulate fraction [3,4]. It was shown subsequently that ISO increased cAMP and PKA in both the soluble and particulate fraction, whereas PGE_1 increased cAMP and PKA in only the soluble fraction [5,6]. These results constitute the initial evidence that the cAMP cascade is confined in distinct intracellular compartments in cardiac cells. Recently, electrophysiological and imaging approaches that resolve cAMP signals at the

subcellular level in intact cardiomyocytes confirmed that cAMP generated by EP-R stimulation has no access to PKAII and does not regulate PKAII targets [7-9]. Moreover, other G_s protein-coupled receptors (G_s PCRs) that increase cAMP were shown to elicit specific responses in cardiomyocytes. This is the case of β_2 -ARs (see below), glucagon receptors (Glu-Rs) [10] and glucagon-like peptide-1 receptors (GLP₁-Rs) [11]. The current view is that each receptor acts through a specific macromolecular complex that transmits the signal to the final effector(s) [12]. Scaffold proteins, and in particular A-kinase anchoring proteins (AKAPs), that tether PKA in the vicinity of its substrates, are key organizers of these complexes (for further information on this topic, see chapter by John Scott *et al.*) [13,14]. Nevertheless, such organization would not be sufficient to ensure specificity if cAMP would freely diffuse inside the cell. In addition to specialized membrane structures that influence the organization of the cAMP cascade, degradation of cAMP by cyclic nucleotide phosphodiesterases (PDEs) appears critical for the formation of dynamic cAMP microdomains. In this chapter, we will briefly summarize these aspects of cAMP signalling compartmentation in heart cells.

Cell architecture

Signal transduction cascades cannot be dissociated from the surrounding cell architecture which determines their organization. This is particularly true in large adult ventricular myocytes, which developed the transverse tubular network to increase the efficiency of ECC. T-tubules are invaginations of the plasma membrane occurring at the sarcomeric Z-line, whose major function is the synchronization of Ca^{2+} release [15]. Together with proteins involved in cellular Ca^{2+} cycling, several components of the cAMP pathway were shown to localize in T-tubules, including G_s proteins, AC type 5 and 6, and AKAPs [16-19]. However, ECC takes place mostly in specialized regions called dyads where T-tubule and SR meet [2]. To our knowledge, the truly

relevant question in terms of cAMP signalling compartmentation, *i.e.* whether β_1 -ARs are specifically enriched in dyads whereas, for instance, prostanoid receptors would be excluded from these domains is still unanswered.

Other microdomains of interest for signal transduction are caveolae. These small invaginations of the plasma membrane enriched in cholesterol and sphingolipids, are defined by their principal structural protein, caveolin 3 in striated muscles [20]. A number of components of the cAMP pathway including GPCRs, G proteins, AC5/6 isoforms and PKA regulatory subunits were shown to segregate between caveolar and non caveolar fractions of the membrane [21-27]. For instance, in canine heart, caveolae contain the type II regulatory subunit of PKA, but not the type I [22]. Also excluded from caveolae, are the prostanoid E2 receptors [24] and this location was suggested to account for the lack of effect of PGE₁ on L-type Ca²⁺ channel current ($I_{Ca,L}$) and cAMP measured with PKAII-based FRET sensors [8]. Ostrom *et al.* (2001) [24] also found both β_1 -ARs and β_2 -ARs in caveolae, together with AC6. However, the group of Steinberg proposed that segregation of β_1 -ARs and β_2 -ARs subtypes, respectively in non caveolar and caveolar domains of the membrane, underlies the functional differences between β -AR subtypes [25]. Indeed, in contrast to β_1 -AR stimulation, in some species activation of β_2 -ARs appears restricted to the plasma membrane and LTCC phosphorylation, thus inducing a modest inotropic effect without hastening relaxation [28,29] (but see [30]). In line with these findings, co-immunoprecipitation experiments identified a macromolecular signalling complex linking β_2 -ARs to LTCCs in cardiomyocyte caveolae [12]. Caveolae disruption with cholesterol binding agents selectively enhances β_2 -ARs but not β_1 -ARs responses [12,26,31,32]. In particular, caveolae disruption allows β_2 -AR stimulation to phosphorylate PLB and TnI, thus accelerating relaxation [32]. Collectively, these observations support the idea that receptor location in distinct

microdomains of the plasma membrane is an important determinant of functional compartmentation.

Receptor coupling to G_i

GPCRs positively coupled to cAMP may not act exclusively through the classical G_s/cAMP/PKA cascade. In particular, certain GPCRs such as histamine, serotonin, and glucagon can also couple to G_i proteins in cardiac cells [33]. However, the best example of such coupling is the β_2 -AR, and this peculiarity has been proposed to explain the distinct effects of β_1 -ARs and β_2 -ARs in cardiomyocytes [34-36]. Indeed, G_i inhibition with pertussis toxin (PTX) specifically potentiates β_2 -AR stimulation of Ca²⁺ transients and contraction [31,32,34,37], and allows β_2 -AR to phosphorylate PLB and accelerate relaxation [36]. Thus, β_2 -AR coupling to G_i appears to circumvent the concurrent G_s/cAMP/PKA activation and to prevent global actions of β_2 -ARs. Surprisingly however, this does not seem to be due to concomitant inhibition of AC since PTX treatment has no effect on β_2 -AR evoked cAMP accumulation or PKA activation [36,38,39]. The mechanisms acting downstream of G_i are not fully elucidated. In rat ventricular myocytes, G_i signaling probably involves activation of phosphatidylinositol-3 kinases (PI3K) and phosphatases, since inhibition of these enzymes reproduce the effects of PTX [36,40]. An alternative signalling pathway, previously shown in chick embryonic myocytes, involves G_i activation of cytosolic phospholipase A2 (cPLA2) [37]. Similarly to PI3K inhibition, cPLA2 inhibition enhances β_2 -AR evoked Ca²⁺ transients and uncovers PLB phosphorylation by PKA. This signaling cascade is recruited to caveolae upon β_2 -AR stimulation [31]. Together, these data are consistent with the hypothesis that spatial restriction of β_2 -AR cAMP signalling by G_i occurs within the context of caveolae [32].

Receptor coupling to different adenylyl cyclase isoforms

The heart expresses several AC isoforms (AC4-6, AC9), among which AC5 and AC6 represent the major forms [41]. AC5 and AC6 share strong similarities in sequence and functional characteristics: both are activated by G_s subunits and forskolin and inhibited by $G_{\alpha i}$ and $G_{\beta \gamma}$ subunits [42,43], Ca^{2+} ions [44,45], and PKA phosphorylation [41,42,46,47]. There are very few evidences that AC5 and AC6 mediate distinct hormonal responses in the heart. However, over-expression of AC6 in neonatal cardiomyocytes selectively enhances β -AR cAMP accumulation vs. EP-R, histamine H2 receptors, Glu-R or adenosine A2-R [23]. A subsequent study in adult cardiomyocytes further demonstrated that AC6 over-expression selectively increased β_1 -AR contractile response but not that of β_2 -AR [48]. In contrast, purinergic receptors seem to couple selectively to AC5 in cardiomyocytes [49].

Restriction of cAMP diffusion

Spatial restriction of cAMP in cardiomyocytes was shown directly by electrophysiological and imaging techniques. Patch clamp recordings of $I_{Ca,L}$ showed that β_2 -ARs are unable to regulate remote LTCC, implying that cAMP diffusion can be strongly restricted [50,51]. The use of fluorescent resonance energy transfer (FRET)-based sensors [39,52] and cyclic nucleotide-gated (CNG) channels [53] to measure directly cAMP in living cells confirmed spatial confinement of the second messenger. Combination of both techniques revealed distinct temporal characteristics of β -AR signals at the membrane and in the cytosol, thus suggesting the existence of cAMP gradients in cardiomyocytes [54]. At least four different mechanisms may explain why cAMP does not diffuse: cAMP buffering, physical barriers, cAMP degradation and cAMP extrusion.

Early biochemical studies and recent models indicate that PKA regulatory subunits can effectively buffer cAMP, and thus likely participate in cAMP compartmentation [55,56]. CNG channel measurements revealed that upon hormonal stimulation cAMP raises to higher level at the plasma membrane than in the bulk cytosol, implying the existence of physical barriers, possibly formed by caveolae and endoplasmic reticulum juxtaposition [57]. Emerging evidence supports the notion that cAMP export, in particular through multidrug resistance-associated proteins 4, may participate in the functional compartmentation of cAMP in certain tissues [58,59]. However, the most documented mechanism for preventing cAMP diffusion in cardiac myocytes is cAMP degradation by cyclic nucleotide phosphodiesterases (PDEs). At present, at least eleven PDE families have been identified, among which PDE1, PDE2, PDE3, and PDE4 are responsible for cAMP degradation in heart [60-62]. Among these, PDE1-3 can hydrolyze both cAMP and cGMP, whereas PDE4 hydrolyzes exclusively cAMP. PDE1 is stimulated by Ca^{2+} -calmodulin; PDE2 is stimulated by cGMP; PDE3 is inhibited by cGMP; and PDE4 is activated by PKA. The PDE1 family is encoded by three genes (PDE1A-C), PDE2 is encoded by one gene (PDE2A), the PDE3 family is encoded by two genes (PDE3A and PDE3B) and PDE4 is encoded by four genes (PDE4A-D). Cardiac myocytes express two forms of PDE2A [63], three forms of PDE3A [64] and >5 forms of PDE4 derived from PDE4A, B and D genes [65,66]. Whether cardiac PDE1 is expressed predominantly in fibroblasts or cardiomyocytes is unknown and might depend on the species considered [67,68]. In addition, the lack of selective inhibitors largely precludes investigation of PDE1 function in cardiomyocytes. In contrast, selective inhibitors of PDE2 (EHNA), PDE3 (cilostamide) and PDE4 (rolipram or Ro 201724) allows dissection of the respective role of these PDEs in cardiac function. Although basal PDE2 activity is much smaller than that of PDE3 and PDE4 in cardiomyocytes, it can effectively suppress β -

AR responses when cGMP levels are elevated [61,69]. However, the main control over ECC is provided by the dominant PDE3 and PDE4 subtypes. PDE3 is about 10 times more sensitive to cAMP than PDE4, which may explain why PDE3 inhibitors exert direct positive inotropic effects especially in large mammals [70], whereas PDE4 exert positive inotropic effects only in the presence of elevated cAMP [62,71].

Role of phosphodiesterases in cardiac cAMP compartmentation

Early evidence for a contribution of PDEs to cAMP compartmentation comes from the differential effect of ISO and PDE inhibitors such as IBMX (a broad spectrum PDE inhibitor) or milrinone (a selective PDE3 inhibitor) on PLB and TnI phosphorylation in guinea pig hearts, [72] which were attributed to different expression of PDEs at the membrane and in the cytosol [70]. In a subsequent study, the fact that PDE inhibition decreased the proportion of particulate vs. cytosolic cAMP suggested that these enzymes limit the amount of cAMP diffusing from the membrane to the cytosol upon β -AR stimulation [73]. Similar conclusions were drawn from $I_{Ca,L}$ or direct cAMP measurements in intact cells with CNG channels or FRET-based biosensors [39,50,52,53]. A number of subsequent studies showed that PDE2, PDE3 and mainly PDE4 shape β -AR cAMP signals in cardiomyocytes [7,54,74-78]. The property of PDE4 long forms to be phosphorylated and activated by PKA [79] and to bind to AKAPs [80] allows efficient suppression of β -AR cAMP by these enzymes (Figure 2) [53,54]. Interestingly, a distinct pattern of PDEs regulate cAMP generated by different G_s PCRs. Indeed, cAMP generated by glucagon receptors is specifically controlled by PDE4, whereas both PDE3 and PDE4 regulate cAMP elicited by β_1 -ARs and β_2 -ARs and both PDE3, PDE4 plus other PDEs regulate EP-R cAMP in adult cardiac myocytes [7]. Studies in mice deficient for the PDE4 genes, and biochemical approaches suggest that products of the PDE4D gene are the dominant PDE4 involved in β -AR

signaling. Indeed, β -AR stimulation of beating frequency is significantly prolonged in neonatal cardiomyocytes lacking the PDE4D gene [81]. In addition, distinct variants of the PDE4D gene were shown to be transiently associated to β_1 -ARs and β_2 -ARs [82,83]. However, the use of dominant negatives approaches rather points to a role of PDE4B2 in the termination of β -AR cAMP signals [76]. This example shows that, although obvious progress were made since the initial proposition that cAMP is compartmentalized, much work remains to be done to provide an exhaustive molecular description of the cAMP signaling pathways in cardiac cells. Understanding these details may not only satisfy academic curiosity, but might also prove useful to envisage new therapeutic strategies in pathological hypertrophy and heart failure. This is suggested by two recent studies in which disruption of a single isoform of PDE3 or PDE4 was shown to favor the development of cardiac dysfunction [84,85].

Acknowledgements

This work was supported by grants from the Fondation Leducq 06CVD02 cycAMP and EU contract LSHM-CT-2005-018833/EUGeneHeart.

Figure legends

Figure 1. Autonomic regulation of cardiac excitation-contraction coupling. Noradrenaline liberated by sympathetic nerves binds to β -ARs (the most classical case of β_1 -ARs is represented) at the surface of cardiac myocytes. β_1 -ARs stimulate cAMP synthesis by adenylyl cyclases (AC) through coupling to Gs proteins. The second messenger in turn activates cAMP-dependent protein kinase (PKA), which phosphorylates a large number of target proteins in cardiomyocytes. Among these, the concerted phosphorylation of L-type Ca^{2+} channels (LTCC), ryanodine receptor subtype 2 (RyR2), phospholamban (PLB) and troponin I (TnI) are responsible for the positive inotropic effect of β -AR stimulation.

Figure 2. Control of β -AR cAMP signals by PDE4 in cardiac myocytes. Upon β -AR stimulation, elevation of cAMP activates PKA (1), which in turn phosphorylates and activates PDE4 (2) to limit cAMP accumulation (3). This negative feedback loop is facilitated by the close proximity of PKA and PDE4 through their binding to the same A-kinase anchoring protein (AKAP).

Figure 1

Figure 2

References

- 1 Steinberg, S. F. and Brunton, L. L. (2001). Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. *Ann Rev Pharmacol Toxicol* **41**, 751-773
- 2 Bers, D. M. (2002). Cardiac excitation-contraction coupling. *Nature* **415**, 198-205
- 3 Corbin, J. D. and Keely, S. L. (1977). Characterization and regulation of heart adenosine 3':5'-monophosphate-dependent protein kinase isozymes. *J Biol Chem* **252**, 910-918
- 4 Corbin, J. D., Sugden, P. H., Lincoln, T. M. and Keely, S. L. (1977). Compartmentalization of adenosine 3':5'-monophosphate and adenosine 3':5'-monophosphate-dependent protein kinase in heart tissue. *J Biol Chem* **252**, 3854-3861
- 5 Hayes, J. S., Brunton, L. L., Brown, J. H., Reese, J. B. and Mayer, S. E. (1979). Hormonally specific expression of cardiac protein kinase activity. *Proc Natl Acad Sci USA* **76**, 1570-1574
- 6 Buxton, I. L. O. and Brunton, L. L. (1983). Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. *J Biol Chem* **258**, 10233-10239
- 7 Rochais, F., Abi-Gerges, A., Horner, K., Lefebvre, F., Cooper, D. M. F., Conti, M., Fischmeister, R. and Vandecasteele, G. (2006). A specific pattern of phosphodiesterases controls the cAMP signals generated by different G_s-coupled receptors in adult rat ventricular myocytes. *Circ Res* **98**, 1081-1088
- 8 Warriar, S., Ramamurthy, G., Eckert, R. L., Nikolaev, V. O., Lohse, M. J. and Harvey, R. D. (2007). cAMP microdomains and L-type Ca²⁺ channel regulation in guinea-pig ventricular myocytes. *J Physiol* **580**, 765-776
- 9 Di Benedetto, G., Zoccarato, A., Lissandron, V., Terrin, A., Li, X., Houslay, M. D., Baillie, G. S. and Zaccolo, M. (2008). Protein kinase A type I and type II define distinct intracellular signaling compartments. *Circ Res* **103**, 836-44
- 10 Farah, A. E. (1983). Glucagon and the heart. *Exp Pharmacol* **53**, 553-609
- 11 Vila Petroff, M. G., Egan, J. M., Wang, X. and Sollott, S. J. (2001). Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. *Circ Res* **89**, 445-452
- 12 Balijepalli, R. C., Foell, J. D., Hall, D. D., Hell, J. W. and Kamp, T. J. (2006). Localization of cardiac L-type Ca²⁺ channels to a caveolar macromolecular signaling complex is required for β_2 -adrenergic regulation. *Proc Natl Acad Sci U S A* **103**, 7500-7505
- 13 Tasken, K. and Aandahl, E. M. (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol Rev* **84**, 137-167
- 14 Dodge-Kafka, K. L., Langeberg, L. and Scott, J. D. (2006). Compartmentation of cyclic

- nucleotide signaling in the heart: the role of A-kinase anchoring proteins. *Circ Res* **98**, 993-1001
- 15 Brette, F. and Orchard, C. (2003). T-tubule function in mammalian cardiac myocytes. *Circ Res* **92**, 1182-92
 - 16 Gao, T. Y., Puri, T. S., Gerhardstein, B. L., Chien, A. J., Green, R. D. and Hosey, M. M. (1997). Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes. *J Biol Chem* **272**, 19401-19407
 - 17 Laflamme, M. A. and Becker, P. L. (1999). G_s and adenylyl cyclase in transverse tubules of heart: implications for cAMP-dependent signaling. *Am J Physiol Heart Circ Physiol* **277**, H1841-H1848
 - 18 Yang, J. C., Drazba, J. A., Ferguson, D. G. and Bond, M. (1998). A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. *J Cell Biol* **142**, 511-522
 - 19 Head, B. P., Patel, H. H., Roth, D. M., Lai, N. C., Niesman, I. R., Farquhar, M. G. and Insel, P. A. (2005). G-protein coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. *J Biol Chem* **280**, 31036-31044
 - 20 Tang, Z., Scherer, P. E., Okamoto, T., Song, K., Chu, C., Kohtz, D. S., Nishimoto, I., Lodish, H. F. and Lisanti, M. P. (1996). Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. *J Biol Chem* **271**, 2255-2261
 - 21 Feron, O., Smith, T. W., Michel, T. and Kelly, R. A. (1997). Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes. *J Biol Chem* **272**, 17744-17748
 - 22 Schwencke, C., Yamamoto, M., Okumura, S., Toya, Y., Kim, S. J. and Ishikawa, Y. (1999). Compartmentation of cyclic adenosine 3',5'-monophosphate signaling in caveolae. *Mol Endocrinol* **13**, 1061-70
 - 23 Ostrom, R. S., Violin, J. D., Coleman, S. and Insel, P. A. (2000). Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: Colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. *Mol Pharmacol* **57**, 1075-1079
 - 24 Ostrom, R. S., Gregorian, C., Drenan, R. M., Xiang, Y., Regan, J. W. and Insel, P. A. (2001). Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. *J Biol Chem* **276**, 42063-42069
 - 25 Rybin, V. O., Xu, X., Lisanti, M. P. and Steinberg, S. F. (2000). Differential targeting of β -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae: a mechanism to functionally regulate the cAMP signaling pathway. *J Biol Chem* **275**, 41447-

- 26 Xiang, Y., Rybin, V. O., Steinberg, S. F. and Kobilka, B. (2002). Caveolar localization dictates physiologic signaling of β_2 -adrenoceptors in neonatal cardiac myocytes. *J Biol Chem* **277**, 34280-34286
- 27 Rybin, V. O., Pak, E., Alcott, S. and Steinberg, S. F. (2003). Developmental changes in beta(2)-adrenergic receptor signaling in ventricular myocytes: the role of Gi proteins and caveolae microdomains. *Mol Pharmacol* **63**, 1338-1348
- 28 Xiao, R. P. and Lakatta, E. G. (1993). β_1 -Adrenoceptor stimulation and β_2 -adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca^{2+} , and Ca^{2+} current in single rat ventricular cells. *Circ Res* **73**, 286-300
- 29 Xiao, R. P., Hohl, C., Altschuld, R. , Jones, L., Livingston, B., Ziman, B., Tantini, B. and Lakatta, E. G. (1994). β_2 -adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca^{2+} dynamics, contractility, or phospholamban phosphorylation. *J Biol Chem* **269**, 19151-19156
- 30 Bartel, S., Krause, E. G., Wallukat, G. and Karczewski, P. (2003). New insights into β_2 -adrenoceptor signaling in the adult rat heart. *Cardiovasc Res* **57**, 694-703
- 31 Ait-Mamar, B., Cailleret, M., Rucker-Martin, C., Bouabdallah, A., Candiani, G., Adamy, C., Duvaldestin, P., Pecker, F., Defer, N. and Pavoine, C. (2005). The cytosolic phospholipase A2 pathway, a safeguard of beta2-adrenergic cardiac effects in rat. **280**, 18881-90
- 32 Calaghan, S. and White, E. (2006). Caveolae modulate excitation-contraction coupling and β_2 -adrenergic signalling in adult rat ventricular myocytes. *Cardiovasc Res* **69**, 816-24
- 33 Kilts, J. D., Gerhardt, M. A., Richardson, M. D., Sreeram, G., Mackensen, G. B., Grocott, H. P., White, W. D., Davis, R. D., Newman, M. F., Reves, J. G., Schwinn, D. A. and Kwatra, M. M. (2000). β_2 -adrenergic and several other G protein-coupled receptors in human atrial membranes activate both Gs and Gi. *Circ Res* **87**, 705-709
- 34 Xiao, R. P., Ji, X. W. and Lakatta, E. G. (1995). Functional coupling of the beta(2)-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. *Mol Pharmacol* **47**, 322-329
- 35 Xiao, R. P., Avdonin, P., Zhou, Y. Y., Chen, H. P., Akhter, S. A., Eschenhagen, T., Lefkowitz, R. J., Koch, W. J. and Lakatta, E. G. (1999). Coupling of β_2 -adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. *Circ Res* **84**, 43-52
- 36 Kuschel, M., Zhou, Y. Y., Cheng, H. P., Zhang, S. J., Chen, Y., Lakatta, E. G. and Xiao, R. P. (1999). Gi protein-mediated functional compartmentalization of cardiac β_2 -adrenergic signaling. *J Biol Chem* **274**, 22048-22052
- 37 Pavoine, C., Magne, S., Sauvadet, A. and Pecker, F. (1999). Evidence for a β_2 -adrenergic

arachidonic acid pathway in ventricular cardiomyocytes - Regulation by the β_1 -adrenergic/cAMP pathway. *J Biol Chem* **274**, 628-637

- 38 Zhou, Y. Y., Cheng, H. P., Bogdanov, K. Y., Hohl, C., Altschuld, R., Lakatta, E. G. and Xiao, R. P. (1997). Localized cAMP-dependent signaling mediates β_2 -adrenergic modulation of cardiac excitation-contraction coupling. *Am J Physiol Heart Circ Physiol* **42**, H1611-H1618
- 39 Nikolaev, V. O., Bunemann, M., Schmitteckert, E., Lohse, M. J. and Engelhardt, S. (2006). Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β_1 -adrenergic but locally confined β_2 -adrenergic receptor-mediated signaling. *Circ Res* **99**, 1084-1091
- 40 Jo, S. H., Leblais, V., Wang, P. H., Crow, M. T. and Xiao, R. P. (2002). Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G_s signaling during β_2 -adrenergic stimulation. *Circ Res* **91**, 46-53
- 41 Defer, N., Best-Belpomme, M. and Hanoune, J. (2000). Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. *Am J Physiol Ren Physiol* **279**, F400-F416
- 42 Sunahara, R. K., Dessauer, C. W. and Gilman, A. G. (1996). Complexity and diversity of mammalian adenylyl cyclases. *Annu Rev Pharmacol Toxicol* **36**, 461-480
- 43 Bayewitch, M. L., Avidor-Reiss, T., Levy, R., Pfeuffer, T., Nevo, I., Simonds, W. F. and Vogel, Z. (1998). Inhibition of adenylyl cyclase isoforms V and VI by various Gbetagamma subunits. *FASEB J* **12**, 1019-1025
- 44 Colvin, R. A., Oibo, J. A. and Allen, R. A. (1991). Calcium inhibition of cardiac adenylyl cyclase - Evidence for two distinct sites of inhibition. *Cell Calcium* **12**, 19-27
- 45 Yu, H. J., Ma, H. and Green, R. D. (1993). Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes. *Mol Pharmacol* **44**, 689-693
- 46 Chen, Y., Harry, A., Li, J., Smit, M. J., Bai, X., Magnusson, R., Pieroni, J. P., Weng, G. and Iyengar, R. (1997). Adenylyl cyclase 6 is selectively regulated by protein kinase A phosphorylation in a region involved in $G\alpha_s$ stimulation. *Proc Natl Acad Sci USA* **94**, 14100-14104
- 47 Hanoune, J. and Defer, N. (2001). Regulation and role of adenylyl cyclase isoforms. *Annu Rev Pharmacol Toxicol* **41**, 145-174
- 48 Stark, J. C., Haydock, S. F., Foo, R., Brown, M. J. and Harding, S. E. (2004). Effect of overexpressed adenylyl cyclase VI on β_1 - and β_2 -adrenoceptor responses in adult rat ventricular myocytes. *Br J Pharmacol* **143**, 465-476
- 49 Pucat, M., Bony, C., Jaconi, M. and Vassort, G. (1998). Specific activation of adenylyl cyclase V by a purinergic agonist. *FEBS Lett* **431**, 189-194

- 50 Jurevicius, J. and Fischmeister, R. (1996). cAMP compartmentation is responsible for a local activation of cardiac Ca^{2+} channels by β -adrenergic agonists. *Proc Natl Acad Sci USA* **93**, 295-299
- 51 Chen-Izu, Y., Xiao, R. P., Izu, L. T., Cheng, H., Kuschel, M., Spurgeon, H. and Lakatta, E. G. (2000). G_i -dependent localization of β_2 -adrenergic receptor signaling to L-type Ca^{2+} channels. *Biophys J* **79**, 2547-2556
- 52 Zaccolo, M. and Pozzan, T. (2002). Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. *Science* **295**, 1711-1715
- 53 Rochais, F., Vandecasteele, G., Lefebvre, F., Lugnier, C., Lum, H., Mazet, J.-L., Cooper, D. M. F. and Fischmeister, R. (2004). Negative feedback exerted by PKA and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes. An *in vivo* study using adenovirus-mediated expression of CNG channels. *J Biol Chem* **279**, 52095-52105
- 54 Leroy, J., Abi-Gerges, A., Nikolaev, V. O., Richter, W., Lechêne, P., Mazet, J.-L., Conti, M., Fischmeister, R. and Vandecasteele, G. (2008). Spatiotemporal dynamics of β -adrenergic cAMP signals and L-type Ca^{2+} channel regulation in adult rat ventricular myocytes: Role of phosphodiesterases. *Circ Res* **102**, 1091-1100
- 55 Beavo, J. A., Bechtel, P. J. and Krebs, E. G. (1974). Activation of protein kinase by physiological concentrations of cyclic AMP. **71**, 3580-3
- 56 Saucerman, J. J., Zhang, J., Martin, J. C., Peng, L. X., Stenbit, A. E., Tsien, R. Y. and McCulloch, A. D. (2006). Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes. *Proc Natl Acad Sci U S A* **103**, 12923-12928
- 57 Rich, T. C., Fagan, K. A., Nakata, H., Schaack, J., Cooper, D. M. F. and Karpen, J. W. (2000). Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMP diffusion. *J Gen Physiol* **116**, 147-161
- 58 Li, C., Krishnamurthy, P. C., Penmatsa, H., Marrs, K. L., Wang, X. Q., Zaccolo, M., Jalink, K., Li, M., Nelson, D. J., Schuetz, J. D. and Naren, A. P. (2007). Spatiotemporal Coupling of cAMP Transporter to CFTR Chloride Channel Function in the Gut Epithelia. *Cell* **131**, 940-951
- 59 Sassi, Y., Lipskaia, L., Vandecasteele, G., Nikolaev, V. O., Hatem, S. N., Cohen Aubart, F., Russel, F. G., Mougenot, N., Vrignaud, C., Lechat, P., Lompre, A. M. and Hulot, J. S. (2008). Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. *J Clin Invest* **118**, 2747-2757
- 60 Beavo, J. A., Francis, S. H. and Houslay, M. D. (2007). Cyclic nucleotide phosphodiesterases in health and disease. *CRC Press, Taylor & Francis Group, Boca Raton, Florida, USA* pp. 1-713
- 61 Fischmeister, R., Castro, L. R. V., Abi-Gerges, A., Rochais, F., Jurevičius, J., Leroy, J. and

- Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide signaling in the heart: The role of cyclic nucleotide phosphodiesterases. *Circ Res* **99**, 816-828
- 62 Osadchii, O., Norton, G. and Woodiwiss, A. (2005). Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. *Eur J Pharmacol* **514**, 201-208
 - 63 Sonnenburg, W. K., Mullaney, P. J. and Beavo, J. A. (1991). Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. **266**, 17655-61
 - 64 Wechsler, J., Choi, Y. H., Krall, J., Ahmad, F., Manganiello, V. C. and Movsesian, M. A. (2002). Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. *J Biol Chem* **277**, 38072-38078
 - 65 Kostic, M. M., Erdogan, S., Rena, G., Borchert, G., Hoch, B., Bartel, S., Scotland, G., Huston, E., Houslay, M. D. and Krause, E. G. (1997). Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. *J Mol Cell Cardiol* **29**, 3135-3146
 - 66 Richter, W., Jin, S. L. and Conti, M. (2005). Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. *Biochem J* **388**, 803-811
 - 67 Bode, D. C., Kanter, J. R. and Brunton, L. L. (1991). Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. *Circ Res* **68**, 1070-1079
 - 68 Vandeput, F., Wolda, S. L., Krall, J., Hambleton, R., Uher, L., McCaw, K. N., Radwanski, P. B., Florio, V. and Movsesian, M. A. (2007). Cyclic nucleotide phosphodiesterase PDE1C in human cardiac myocytes. *J Biol Chem* doi:10.1074/jbc.M703173200
 - 69 Richter, W., Jin, S. L. and Conti, M. (2005). Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. **388**, 803-11
 - 70 Weishaar, R. E., Kobylarz-Singer, D. C., Steffen, R. P. and Kaplan, H. R. (1987). Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. *Circ Res* **61**, 539-547
 - 71 Lugnier, C. (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. *Pharmacol Ther* **109**, 366-398
 - 72 Rapundalo, S. T., Solaro, R. J. and Kranias, E. G. (1989). Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. *Circ Res* **64**, 104-111
 - 73 Hohl, C. M. and Li, Q. (1991). Compartmentation of cAMP in adult canine ventricular myocytes - Relation to single-cell free Ca²⁺ transients. *Circ Res* **69**, 1369-1379

- 74 Verde, I., Vandecasteele, G., Lezoualc'h, F. and Fischmeister, R. (1999). Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca^{2+} current in rat ventricular myocytes. *Br J Pharmacol* **127**, 65-74
- 75 Jurevicius, J., Skeberdis, V. A. and Fischmeister, R. (2003). Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following β_2 -adrenergic stimulation of $\text{I}_{\text{Ca,L}}$ in frog ventricular myocytes. *J Physiol* **551**, 239-252
- 76 Mongillo, M., McSorley, T., Evellin, S., Sood, A., Lissandron, V., Terrin, A., Huston, E., Hannawacker, A., Lohse, M. J., Pozzan, T., Houslay, M. D. and Zaccolo, M. (2004). Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. *Circ Res* **95**, 65-75
- 77 Dittrich, M., Jurevicius, J., Georget, M., Rochais, F., Fleischmann, B. K., Hescheler, J. and Fischmeister, R. (2001). Local response of L-type Ca^{2+} current to nitric oxide in frog ventricular myocytes. *J Physiol* **534**, 109-121
- 78 Mongillo, M., Tocchetti, C. G., Terrin, A., Lissandron, V., Cheung, Y. F., Dostmann, W. R., Pozzan, T., Kass, D. A., Paolocci, N., Houslay, M. D. and Zaccolo, M. (2006). Compartmentalized phosphodiesterase-2 activity blunts β -adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. *Circ Res* **98**, 226-234
- 79 Sette, C. and Conti, M. (1996). Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase - Involvement of serine 54 in the enzyme activation. *J Biol Chem* **271**, 16526-16534
- 80 Dodge, K. L., Khouangsathiene, S., Kapiloff, M. S., Mouton, R., Hill, E. V., Houslay, M. D., Langeberg, L. K. and Scott, J. D. (2001). mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. *EMBO J* **20**, 1921-1930
- 81 Xiang, Y., Naro, F., Zoudilova, M., Jin, S. L., Conti, M. and Kobilka, B. (2005). Phosphodiesterase 4D is required for β_2 adrenoceptor subtype-specific signaling in cardiac myocytes. *Proc Natl Acad Sci USA* **102**, 909-914
- 82 Baillie, G. S., Sood, A., McPhee, I., Gall, I., Perry, S. J., Lefkowitz, R. J. and Houslay, M. D. (2003). β -Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β -adrenoceptor switching from G_s to G_i . *Proc Natl Acad Sci USA* **100**, 941-945
- 83 Richter, W., Day, P., Agraval, R., Bruss, M. D., Granier, S., Wang, Y. L., Rasmussen, S. G. F., Horner, K., Wang, P., Lei, T., Patterson, A. J., Kobilka, B. K. and Conti, M. (2008). Signaling from β_1 - and β_2 -adrenergic receptors is defined by differential interactions with PDE4. *Embo J* **27**, 384-393
- 84 Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., Silengo, L., Altruda, F., Wetzker, R., Wymann, M. P., Lembo, G. and Hirsch, E. (2004). PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent

effects. *Cell* **118**, 375-387

- 85 Lehnart, S. E., Wehrens, X. H. T., Reiken, S., Warrier, S., Belevych, A. E., Harvey, R. D., Richter, W., Jin, S. L. C., Conti, M. and Marks, A. (2005). Phosphodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. *Cell* **123**, 23-35